Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules Jun 5, 2025
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) Jun 4, 2025
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update May 13, 2025
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 May 7, 2025
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update Mar 13, 2025
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 Mar 5, 2025
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference Feb 5, 2025
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference Jan 12, 2025
